{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T10:25:42Z","timestamp":1774347942283,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00105-026-05664-8","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:12:28Z","timestamp":1772010748000},"page":"272-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Okul\u00e4re Rosazea","Ocular rosacea"],"prefix":"10.1007","volume":"77","author":[{"given":"Louise","family":"Partzsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f6ren","family":"Korsing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"5664_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/bjd.18420","volume":"182","author":"M Schaller","year":"2020","unstructured":"Schaller\u00a0M, Almeida\u00a0LMC, Bewley\u00a0A (2020) Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol 182:1269\u20131276","journal-title":"Br J Dermatol"},{"key":"5664_CR2","first-page":"282","volume":"179","author":"L Gether","year":"2018","unstructured":"Gether\u00a0L, Overgaard\u00a0LK, Egeberg\u00a0A, Thyssen\u00a0JP (2018) Incidence and prevalence of rosacea: a\u00a0systematic review and meta-analysis. Br J Dermatol 179:282\u2013289","journal-title":"Br J Dermatol"},{"key":"5664_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/jamadermatol.2022.0526","volume":"158","author":"YA Barakji","year":"2022","unstructured":"Barakji\u00a0YA, R\u00f8nnstad\u00a0ATM, Christensen\u00a0MO (2022) Assessment of frequency of rosacea subtypes in patients with rosacea: A\u00a0systematic review and meta-analysis. JAMA Dermatol 158:617\u2013625","journal-title":"JAMA Dermatol"},{"key":"5664_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bjd.15173","volume":"176","author":"M Schaller","year":"2017","unstructured":"Schaller\u00a0M, Almeida\u00a0LM, Bewley\u00a0A (2017) Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol 176:465\u2013471","journal-title":"Br J Dermatol"},{"key":"5664_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00403-025-03982-w","volume":"317","author":"S Sharifi","year":"2025","unstructured":"Sharifi\u00a0S, Katamanin\u00a0O, Jafferany\u00a0M (2025) Exploring the psychodermatologic burden and associated psychiatric manifestations in rosacea: a\u00a0systemic review. Arch Dermatol Res 317:427","journal-title":"Arch Dermatol Res"},{"key":"5664_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jad.2021.12.008","volume":"299","author":"HC Chang","year":"2022","unstructured":"Chang\u00a0HC, Huang\u00a0YC, Lien\u00a0YJ, Chang\u00a0YS (2022) Association of rosacea with depression and anxiety: A\u00a0systematic review and meta-analysis. J\u00a0Affect Disord 299:239\u2013245","journal-title":"J Affect Disord"},{"key":"5664_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15693","author":"S Korsing","year":"2025","unstructured":"Korsing\u00a0S, Stieler\u00a0K, Pleyer\u00a0U, Blume-Peytavi\u00a0U, Vogt\u00a0A (2025) Rosacea in childhood and adolescence: A\u00a0review. J\u00a0Dtsch Dermatol Ges. https:\/\/doi.org\/10.1111\/ddg.15693","journal-title":"J Dtsch Dermatol Ges"},{"key":"5664_CR8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1067\/mjd.2002.120625","volume":"46","author":"J Wilkin","year":"2002","unstructured":"Wilkin\u00a0J, Dahl\u00a0M, Detmar\u00a0M (2002) Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J\u00a0Am Acad Dermatol 46:584\u2013587","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"5664_CR9","first-page":"22","volume":"16","author":"MMD van der Linden","year":"2023","unstructured":"van der Linden\u00a0MMD, Arents\u00a0BWM, van Zuuren\u00a0EJ (2023) Diagnosis and treatment of Morbihan\u2019s disease: A\u00a0practical approach based on review of the literature. J\u00a0Clin Aesthet Dermatol 16(10):22\u201330","journal-title":"J Clin Aesthet Dermatol"},{"key":"5664_CR10","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/ijd.16235","volume":"61","author":"S Zierl","year":"2022","unstructured":"Zierl\u00a0S, Hildebrand\u00a0JA, Guertler\u00a0A (2022) Clinical clues to identify patients with ocular rosacea\u2014a\u00a0Germany-wide epidemiologic analysis. Int J Dermatol 61:880\u2013885","journal-title":"Int J Dermatol"},{"key":"5664_CR11","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/S0161-6420(97)30015-3","volume":"104","author":"EK Akpek","year":"1997","unstructured":"Akpek\u00a0EK, Merchant\u00a0A, Pinar\u00a0V, Foster\u00a0CS (1997) Ocular rosacea: patient characteristics and follow-up. Ophthalmology 104:1863\u20131867","journal-title":"Ophthalmology"},{"key":"5664_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/ICO.0000000000000393","volume":"34","author":"M Palamar","year":"2015","unstructured":"Palamar\u00a0M, Degirmenci\u00a0C, Ertam\u00a0I, Yagci\u00a0A (2015) Evaluation of dry eye and meibomian gland dysfunction with meibography in patients with rosacea. Cornea 34:497\u2013499","journal-title":"Cornea"},{"key":"5664_CR13","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.3390\/jcm10132897","volume":"10","author":"YR Woo","year":"2021","unstructured":"Woo\u00a0YR, Cho\u00a0M, Ju\u00a0HJ (2021) Ocular comorbidities in rosacea: A\u00a0case-control study based on seven institutions. J\u00a0Clin Med 10:2897","journal-title":"J Clin Med"},{"key":"5664_CR14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1542-0124(12)70150-7","volume":"2","author":"WE Shine","year":"2004","unstructured":"Shine\u00a0WE, McCulley\u00a0JP (2004) Meibomian gland dysfunction and the tear film. Ocul Surf 2:149\u2013165","journal-title":"Ocul Surf"},{"key":"5664_CR15","first-page":"323","volume":"27","author":"D Rodrigues-Braz","year":"2021","unstructured":"Rodrigues-Braz\u00a0D, Zhao\u00a0M, Yesilirmak\u00a0N (2021) Cutaneous and ocular rosacea: Common and specific physiopathogenic mechanisms and study models. Mol Vis 27:323\u2013353","journal-title":"Mol Vis"},{"key":"5664_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1590\/S0004-27492012000500016","volume":"75","author":"AC Vieira","year":"2012","unstructured":"Vieira\u00a0AC, H\u00f6fling-Lima\u00a0AL, Mannis\u00a0MJ (2012) Ocular rosacea\u2014a review. Arq Bras Oftalmol 75:363\u2013369","journal-title":"Arq Bras Oftalmol"},{"key":"5664_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40257-020-00546-8","volume":"21","author":"HS Kim","year":"2020","unstructured":"Kim\u00a0HS (2020) Microbiota in Rosacea. J\u00a0Am Clin Dermatol 21:25\u201335","journal-title":"J Am Clin Dermatol"},{"key":"5664_CR18","first-page":"e541","volume":"95","author":"S Mizoguchi","year":"2017","unstructured":"Mizoguchi\u00a0S, Iwanishi\u00a0H, Arita\u00a0R (2017) Ocular surface inflammation associated with rosacea: clinical and in vivo confocal microscopy findings. Acta Ophthalmol 95:e541\u2013e549","journal-title":"Acta Ophthalmol"},{"key":"5664_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jtos.2017.01.006","volume":"15","author":"G Geerling","year":"2017","unstructured":"Geerling\u00a0G, Baudouin\u00a0C, Aragona\u00a0P (2017) Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting. Ocul Surf 15:179\u2013192","journal-title":"Ocul Surf"},{"key":"5664_CR20","first-page":"888","volume":"18","author":"SM Johnson","year":"2019","unstructured":"Johnson\u00a0SM, Berg\u00a0A, Barr\u00a0C (2019) Recognizing rosacea: tips on differential diagnosis. J\u00a0Drugs Dermatol 18:888\u2013894","journal-title":"J Drugs Dermatol"},{"key":"5664_CR21","first-page":"185","volume":"20","author":"A G\u00fcrtler","year":"2022","unstructured":"G\u00fcrtler\u00a0A, Laurenz\u00a0S (2022) The impact of clinical nutrition on inflammatory skin diseases. J\u00a0Dtsch Dermatol Ges 20:185\u2013202","journal-title":"J Dtsch Dermatol Ges"},{"key":"5664_CR22","doi-asserted-by":"crossref","unstructured":"Reinholz M, Clanner-Engelshofen B, Schaller M (2022) S2k-Leitlinie Rosazea. AWMF-Registernr: 13\u201365","DOI":"10.1111\/ddg.14849_g"},{"key":"5664_CR23","first-page":"607","volume":"9","author":"JQ Del Rosso","year":"2010","unstructured":"Del Rosso\u00a0JQ, Bruce\u00a0S, Jarratt\u00a0M (2010) Efficacy of topical azelaic acid (AzA) gel 15\u202f% plus oral doxycycline 40\u202fmg versus metronidazole gel 1\u202f% plus oral doxycycline 40\u202fmg in mild-to-moderate papulopustular rosacea. J\u00a0Drugs Dermatol 9:607\u2013613","journal-title":"J Drugs Dermatol"},{"key":"5664_CR24","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jaad.2019.05.063","volume":"82","author":"M Schaller","year":"2020","unstructured":"Schaller\u00a0M, Kem\u00e9ny\u00a0L, Havlickova\u00a0B (2020) A randomized phase\u00a03b\/4\u00a0study to evaluate concomitant use of topical ivermectin 1\u202f% cream and doxycycline 40-mg modified-release capsules versus topical ivermectin 1\u202f% cream and placebo in the treatment of severe rosacea. J\u00a0Am Acad Dermatol 82:336\u2013343","journal-title":"J Am Acad Dermatol"},{"key":"5664_CR25","first-page":"573","volume":"7","author":"JQ Del Rosso","year":"2008","unstructured":"Del Rosso\u00a0JQ, Schlessinger\u00a0J, Werschler\u00a0P (2008) Comparison of anti-inflammatory dose doxycycline versus doxycycline 100\u202fmg in the treatment of rosacea. J\u00a0Drugs Dermatol 7:573\u2013576","journal-title":"J Drugs Dermatol"},{"key":"5664_CR26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","volume":"56","author":"JQ Del Rosso","year":"2007","unstructured":"Del Rosso\u00a0JQ, Webster\u00a0GF, Jackson\u00a0M (2007) Two randomized phase\u00a0III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J\u00a0Am Acad Dermatol 56:791\u2013802","journal-title":"J Am Acad Dermatol"},{"key":"5664_CR27","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3109\/02713683.2015.1122810","volume":"41","author":"R Bhargava","year":"2016","unstructured":"Bhargava\u00a0R, Chandra\u00a0M, Bansal\u00a0U (2016) A randomized controlled trial of omega 3 fatty acids in rosacea patients with dry eye symptoms. Curr Eye Res 41:1274\u20131280","journal-title":"Curr Eye Res"},{"key":"5664_CR28","first-page":"544","volume":"8","author":"A Arman","year":"2015","unstructured":"Arman\u00a0A, Demirseren\u00a0DD, Takmaz\u00a0T (2015) Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline. Int J Ophthalmol 8:544\u2013549","journal-title":"Int J Ophthalmol"},{"key":"5664_CR29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.5935\/0004-2749.20180093","volume":"81","author":"B Bilgin","year":"2018","unstructured":"Bilgin\u00a0B, Karadag\u00a0AS (2018) Effects of combined oral doxycycline and topical cyclosporine treatment on ocular signs, symptoms, and tear film parameters in rosacea patients. Arq Bras Oftalmol 81:466\u2013470","journal-title":"Arq Bras Oftalmol"},{"key":"5664_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1468-3083.2009.03132.x","volume":"23","author":"O Bakar","year":"2009","unstructured":"Bakar\u00a0O, Demircay\u00a0Z, Toker\u00a0E, Cakir\u00a0S (2009) Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J\u00a0Eur Acad Dermatol Venereol 23:544\u2013549","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5664_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000489092","volume":"60","author":"L Lam-Franco","year":"2018","unstructured":"Lam-Franco\u00a0L, Perfecto-Avalos\u00a0Y, Pati\u00f1o-Ram\u00edrez\u00a0BE, Rodr\u00edguez Garc\u00eda\u00a0A (2018) IL-1\u03b1 and MMP\u20119 tear levels of patients with active ocular rosacea before and after treatment with systemic azithromycin or doxycycline. Ophthalmic Res 60:109\u2013114","journal-title":"Ophthalmic Res"},{"key":"5664_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/ceo.12666","volume":"44","author":"A Al-Hity","year":"2016","unstructured":"Al-Hity\u00a0A, Lockington\u00a0D (2016) Oral azithromycin as the systemic treatment of choice in the treatment of meibomian gland disease. Clin Exp Ophthalmol 44:199\u2013201","journal-title":"Clin Exp Ophthalmol"},{"key":"5664_CR33","first-page":"1130","volume":"29","author":"B Sobolewska","year":"2020","unstructured":"Sobolewska\u00a0B, Doycheva\u00a0D, Deuter\u00a0CM (2020) Efficacy of topical ivermectin for the treatment of cutaneous and ocular rosacea. Ocul Immunol Inflamm 29:1130\u20131134","journal-title":"Ocul Immunol Inflamm"},{"key":"5664_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/09273949309086544","volume":"1","author":"J Fruchtpery","year":"1993","unstructured":"Fruchtpery\u00a0J, Sagi\u00a0E (1993) The use of doxycycline and tetracycline in ocular rosacea. Ocul Immunol Inflamm 1:99\u2013104","journal-title":"Ocul Immunol Inflamm"},{"key":"5664_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/ICO.0b013e31802e3a54","volume":"26","author":"KE Donaldson","year":"2007","unstructured":"Donaldson\u00a0KE, Karp\u00a0CL, Dunbar\u00a0MT (2007) Evaluation and treatment of children with ocular rosacea. Cornea 26:42\u201346","journal-title":"Cornea"},{"key":"5664_CR36","doi-asserted-by":"publisher","first-page":"126531","DOI":"10.1016\/j.jtemb.2020.126531","volume":"61","author":"A Waszczykowska","year":"2020","unstructured":"Waszczykowska\u00a0A, Zyro\u00a0D, Jurowski\u00a0P, Ochocki\u00a0J (2020) Effect of treatment with silver(I) complex of metronidazole on ocular rosacea. J\u00a0Trace Elem Med Biol 61:126531","journal-title":"J Trace Elem Med Biol"},{"key":"5664_CR37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jfo.2011.07.008","volume":"34","author":"S Leoni","year":"2011","unstructured":"Leoni\u00a0S, Mesplie\u00a0N, Aitali\u00a0F (2011) Metronidazole: alternative treatment for ocular and cutaneous rosacea in the pediatric population. J\u00a0Fr Ophtalmol 34:703\u2013710","journal-title":"J Fr Ophtalmol"},{"key":"5664_CR38","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1684\/ejd.2022.4301","volume":"32","author":"C Verg\u00e9s","year":"2022","unstructured":"Verg\u00e9s\u00a0C, de Ribot\u00a0MF, Salgado-Borges\u00a0J, Gonzalez\u00a0J (2022) Prospective evaluation of intense pulsed light treatment for meibomian gland dysfunction and blepharitis due to ocular rosacea. Eur J Dermatol 32:505\u2013515","journal-title":"Eur J Dermatol"},{"key":"5664_CR39","first-page":"167","volume":"22","author":"S Avraham","year":"2024","unstructured":"Avraham\u00a0S, Khaslavsky\u00a0S, Kashetsky\u00a0N (2024) Treatment of ocular rosacea: a\u00a0systematic review. J\u00a0Dtsch Dermatol Ges 22:167\u2013174","journal-title":"J Dtsch Dermatol Ges"},{"key":"5664_CR40","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1709691","volume":"378","author":"EJ van Zuuren","year":"2018","unstructured":"van Zuuren\u00a0EJ, Fedorowicz\u00a0Z, Tan\u00a0J (2018) Interventions for rosacea. N\u00a0Engl J Med 378:1681\u20131690","journal-title":"N Engl J Med"},{"key":"5664_CR41","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1055\/s-2006-926720","volume":"223","author":"B Gra\u010dner","year":"2006","unstructured":"Gra\u010dner\u00a0B, Pahor\u00a0D, Gra\u010dner\u00a0T (2006) Behandlung einer umfangreichen Korneoskleraperforation bei okul\u00e4rer Rosacea mit der Keratoplastik. Klin Monbl Augenheilkd 223:841\u2013843","journal-title":"Klin Monbl Augenheilkd"},{"key":"5664_CR42","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jaad.2017.09.016","volume":"78","author":"R Haber","year":"2018","unstructured":"Haber\u00a0R, El Gemayel\u00a0M (2018) Comorbidities in rosacea: A\u00a0systematic review and update. J\u00a0Am Acad Dermatol 78:786\u2013792.e8","journal-title":"J Am Acad Dermatol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05664-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05664-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05664-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:03:11Z","timestamp":1774335791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05664-8"}},"subtitle":["Klinik, Diagnostik, Management und Therapie","Clinical aspects, diagnostics, management and treatment"],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["5664"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05664-8","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"25 February 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"L.\u00a0Partzsch\n                      : A.\u00a0Finanzielle Interessen: L.\u00a0Partzsch gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte \u00c4rztin in Weiterbildung zur Fach\u00e4rztin f\u00fcr Augenheilkunde an der Augenklinik der Charit\u00e9\u00a0\u2013 Universit\u00e4tsmedizin Berlin, Campus Virchow Klinikum | Mitgliedschaft: DOG.\n                      K.\u00a0Nguyen\n                      : A.\u00a0Finanzielle Interessen: K.\u00a0Nguyen gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenz\u00e4rztin, Dermatologie der Charit\u00e9\u00a0\u2013 Universit\u00e4tsmedizin Berlin, Campus Virchow Klinikum.\n                      S.\u00a0Korsing\n                      : A.\u00a0Finanzielle Interessen: S.\u00a0Korsing gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Funktionsoberarzt, Dermatologie der Charit\u00e9\u00a0\u2013 Universit\u00e4tsmedizin Berlin, Campus Virchow Klinikum.\n                      U.\u00a0Pleyer\n                      : A.\u00a0Finanzielle Interessen: Deutsche Forschungsgemeinschaft, BMBF, European Union.\u00a0\u2013 Honorare: AbbVie, Alcon, Allergan, Alimera, Bausch und Lomb, Bayer, Novartis, Santen, Thea | Vortragshonorar.\u00a0\u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00c4.: AbbVie: Erstellung Webinar.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt, Klinik f\u00fcr Augenheilkunde, Charit\u00e9 Universit\u00e4tsmedizin Berlin | Mitgliedschaft\/Funktion in Interessenverb\u00e4nden: Sprecher der Sektion: Uveitis\/DOG seit 2014, Schwerpunkt wissenschaftlicher klinischer T\u00e4tigkeiten: Leiter der Sprechstunde \u201eTerti\u00e4rzentrum f\u00fcr entz\u00fcndliche Augenerkrankungen\u201c 1994 bis heute, bis 2022 Sekret\u00e4r: Berlin-Brandenburgische Augen\u00e4rzte, bis 2022 Vorstandsmitglied: Deutsche UVEITIS Arbeitsgemeinschaft DUAG e.\u202fV. | U.\u00a0Pleyer ist Mitglied des Herausgeberboards von\n                      Die Ophthalmologie\n                      . Er war nicht an der Begutachtung dieses Manuskripts oder an Entscheidungen in Bezug auf dieses Manuskript beteiligt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}